Could Amarin Reject a Buyout?

The thought on everyone's mind when looking at Amarin (Nasdaq: AMRN  ) as an investor right now is: What approach is the company going to take in commercializing its new hypertriglyceridemia drug, Vascepa? Many people consider the company a potential acquisition target; others thought it would seek a partnership before going forward. But after the release of yesterday's conference call, the evidence might suggest that it plans to commercialize Vascepa on its own, an option that previously had some investors a little apprehensive. Motley Fool health care analyst Max Macaluso talks in this video about his take on Amarin's strategy going forward and why the CEO's words were well-received by the market.

The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of Vascepa is key to the company's future success or failure, so the decisions the company makes in the coming months are going to be crucial. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2104903, ~/Articles/ArticleHandler.aspx, 4/18/2014 11:11:56 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement